Skip to main content
. 2000 Aug 15;20(16):6218–6224. doi: 10.1523/JNEUROSCI.20-16-06218.2000

Fig. 6.

Fig. 6.

Mean SWD duration ± SEM of mGluR4+/+ mice treated with CPPG orl-AP4 given intra-nRT before induction of absence seizures with either PTZ or GHB. A, Mean SWD duration ± SEM for mGluR4+/+ mice (n = 10 for each group) that received 100 mg/kg of GBL 10 min after bilateral intra-nRT infusion of 5 nmol of the mGluR4 antagonist CPPG, the mGluR4 agonist l-AP4, or vehicle control. There was no significant (p > 0.1, ANOVA) difference in SWD duration among any of the nRT treatment groups. B, Mean SWD duration ± SEM for mGluR4+/+ mice (n = 10 for each group) that received 30 mg/kg of PTZ 10 min after bilateral intra-nRT infusion of 5 nmol of the mGluR4 antagonist CPPG or vehicle control. Intra-nRT infusion of CPPG conferred significant (p < 0.001, ANOVA) resistance to absence seizures induced by low doses of PTZ.C, Mean SWD duration ± SEM for mGluR4+/+ mice (n = 10 for each group) that received 30 mg/kg of PTZ 10 min after bilateral intra-nRT infusion of 5 nmol of the mGluR4 agonist l-AP4 or vehicle control. l-AP4 administration into the nRT significantly (p < 0.001, ANOVA) exacerbated absence seizures induced by low doses of PTZ.